MARKET

IMMP

IMMP

Immutep
NASDAQ
0.4500
-0.0346
-7.14%
Opening 10:53 03/16 EDT
OPEN
0.4900
PREV CLOSE
0.4846
HIGH
0.4944
LOW
0.4364
VOLUME
4.27M
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
0.4364
MARKET CAP
66.32M
P/E (TTM)
-1.1774
1D
5D
1M
3M
1Y
5Y
1D
Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
TipRanks · 4h ago
Weekly Report: what happened at IMMP last week (0309-0313)?
Weekly Report · 4h ago
*Immutep Price Target Cut 98% to A$0.04/Share by Jefferies
Dow Jones · 17h ago
*Immutep Downgraded to Hold from Buy by Jefferies
Dow Jones · 17h ago
Analysts Conflicted on These Healthcare Names: Immutep (IMMP) and Ultragenyx Pharmaceutical (RARE)
TipRanks · 1d ago
Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early
Benzinga · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 2d ago
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.